Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.

Baertsch MA, Schlenzka J, Lisenko K, Krzykalla J, Becker N, Weisel K, Noppeney R, Martin H, Lindemann HW, Haenel M, Nogai A, Scheid C, Salwender H, Fenk R, Graeven U, Reimer P, Schmidt-Hieber M, Goerner M, Schmidt-Wolf IGH, Klein S, Ho AD, Goldschmidt H, Wuchter P.

Eur J Haematol. 2017 Jul;99(1):42-50. doi: 10.1111/ejh.12888. Epub 2017 May 24.


[Space-occupying lesion in the maxillary sinus].

Lohneis P, Nogai A, Niehues SM, Jöhrens K, Anagnostopoulos I.

Pathologe. 2016 Nov;37(6):568-572. German.


Organ siderosis and hemophagocytosis during acute graft-versus-host disease.

Nogai A, Shi Y, Pérez-Hernandez D, Cordes S, Mengwasser J, Mertlitz S, Riesner K, Kalupa M, Erdmann JH, Ziebig R, Dittmar G, Penack O.

Haematologica. 2016 Aug;101(8):e344-6. doi: 10.3324/haematol.2016.144519. Epub 2016 May 19. No abstract available.


Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.

Baertsch MA, Schlenzka J, Mai EK, Merz M, Hillengaß J, Raab MS, Hose D, Wuchter P, Ho AD, Jauch A, Hielscher T, Kunz C, Luntz S, Klein S, Schmidt-Wolf IG, Goerner M, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Salwender H, Scheid C, Nogai A, Haenel M, Lindemann HW, Martin H, Noppeney R, Weisel K, Goldschmidt H.

BMC Cancer. 2016 Apr 25;16:290. doi: 10.1186/s12885-016-2321-2.


Multiple myeloma cells modify VEGF/IL-6 levels and osteogenic potential of bone marrow stromal cells via Notch/miR-223.

Berenstein R, Nogai A, Waechter M, Blau O, Kuehnel A, Schmidt-Hieber M, Kunitz A, Pezzutto A, Dörken B, Blau IW.

Mol Carcinog. 2016 Dec;55(12):1927-1939. doi: 10.1002/mc.22440. Epub 2015 Nov 24.


Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region.

Berenstein R, Blau O, Nogai A, Waechter M, Slonova E, Schmidt-Hieber M, Kunitz A, Pezzutto A, Doerken B, Blau IW.

BMC Cancer. 2015 Feb 18;15:68. doi: 10.1186/s12885-015-1078-3.


Chronic graft versus host disease but not the intensity of conditioning has impact on survival after allogeneic hematopoietic stem cell transplantation for advanced hematological diseases.

Hilgendorf I, Wolff D, Nogai A, Kundt G, Hahn J, Holler E, Uharek L, Junghanss C, Leithäuser M, Thiel E, Freund M, Kahl C.

Onkologie. 2012;35(9):487-92. Epub 2012 Aug 13.


MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease.

Heimesaat MM, Nogai A, Bereswill S, Plickert R, Fischer A, Loddenkemper C, Steinhoff U, Tchaptchet S, Thiel E, Freudenberg MA, Göbel UB, Uharek L.

Gut. 2010 Aug;59(8):1079-87. doi: 10.1136/gut.2009.197434.


The type of ATG matters -- natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius.

Penack O, Fischer L, Gentilini C, Nogai A, Muessig A, Rieger K, Ganepola S, Thiel E, Uharek L.

Transpl Immunol. 2007 Nov;18(2):85-7. Epub 2007 Jun 12.


Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantation.

Penack O, Fischer L, Stroux A, Gentilini C, Nogai A, Muessig A, Rieger K, Ganepola S, Herr W, Meyer RG, Thiel E, Uharek L.

Bone Marrow Transplant. 2008 Feb;41(4):377-83. Epub 2007 Nov 5.


A novel method to quantify and characterize leukemia-reactive natural killer cells in patients undergoing allogeneic hematopoietic stem cell transplantation following conventional or reduced-dose conditioning.

Penack O, Fischer L, Stroux A, Gentilini C, Nogai A, Muessig A, Ganepola S, Lange T, Kliem C, Marinets O, Blau IW, Thiel E, Uhareka L.

Int J Hematol. 2007 May;85(4):326-32.


Error management of emergency transfusions: a surveillance system to detect safety risks in day to day practice.

Schmidt-Hieber M, Schuster R, Nogai A, Thiel E, Hopfenmüller W, Notter M.

Transfus Apher Sci. 2006 Oct;35(2):125-30. Epub 2006 Oct 12.


The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.

Fischer L, Penack O, Gentilini C, Nogai A, Muessig A, Thiel E, Uharek L.

Exp Hematol. 2006 Jun;34(6):753-9.


Lipopolysaccharide injection induces relapses of experimental autoimmune encephalomyelitis in nontransgenic mice via bystander activation of autoreactive CD4+ cells.

Nogai A, Siffrin V, Bonhagen K, Pfueller CF, Hohnstein T, Volkmer-Engert R, Brück W, Stadelmann C, Kamradt T.

J Immunol. 2005 Jul 15;175(2):959-66.


Cross-reactivity of myelin basic protein-specific T cells with multiple microbial peptides: experimental autoimmune encephalomyelitis induction in TCR transgenic mice.

Grogan JL, Kramer A, Nogai A, Dong L, Ohde M, Schneider-Mergener J, Kamradt T.

J Immunol. 1999 Oct 1;163(7):3764-70.

Supplemental Content

Support Center